Kamada (NASDAQ:KMDA) Given “Buy” Rating at HC Wainwright

Kamada (NASDAQ:KMDA)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $11.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 54.93% from the stock’s previous close.

Kamada Trading Up 7.4 %

Shares of KMDA opened at $7.10 on Thursday. The stock has a 50 day moving average of $7.06 and a 200 day moving average of $6.13. Kamada has a 12 month low of $4.74 and a 12 month high of $9.15. The company has a market capitalization of $408.11 million, a price-to-earnings ratio of 25.36, a PEG ratio of 0.97 and a beta of 0.99.

Hedge Funds Weigh In On Kamada

A number of hedge funds and other institutional investors have recently made changes to their positions in KMDA. Geode Capital Management LLC grew its position in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 1,549 shares during the period. Aristides Capital LLC boosted its stake in Kamada by 12.1% in the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares during the last quarter. NewEdge Advisors LLC grew its position in shares of Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 8,260 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Kamada during the 4th quarter worth approximately $67,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Kamada in the 3rd quarter worth approximately $77,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.